原代人肝细胞诱导脂肪变性可重现代谢功能障碍相关脂肪性肝病的关键病理生理特征
研究建立并表征了原代人肝细胞体外模型:5名不同性别和种族供体的冷冻保存原代人肝细胞在3D胶原三明治中与游离脂肪酸共培养7天,出现脂肪变性、胰岛素抵抗、线粒体功能障碍、炎症及类似MASLD患者的人类基因特征改变;法索司他(firsocostat,GS-0976)可逆转上述病理表现。作者认为该模型可作为临床前预筛选平台,指导MASLD治疗靶点识别与验证。
要点
- 5名供体的原代人肝细胞在3D胶原三明治中与游离脂肪酸共培养7天可诱导脂肪变性。
- 该模型重现胰岛素抵抗、线粒体功能障碍、炎症及类似MASLD患者的基因特征。
- 法索司他(firsocostat,GS-0976)可逆转模型中观察到的脂肪肝病理表现。
核心结论
- 原代人肝细胞脂肪变性体外模型可重现MASLD的关键病理生理特征,并可用于测试候选药物的疗效和潜在作用机制。
- 作者认为该模型可作为临床前预筛选平台,指导MASLD治疗靶点的识别与验证。
研究设计与样本
- 体外研究:5名性别和种族不同的供体提供的冷冻保存原代人肝细胞,在3D胶原三明治中与游离脂肪酸共培养7天。
- 通过评估经典肝细胞功能追踪MASLD发展,并以法索司他(firsocostat,GS-0976)进行概念验证。
主要发现
- 游离脂肪酸孵育诱导脂肪变性、胰岛素抵抗、线粒体功能障碍、炎症及类似MASLD患者的人类基因特征改变。
- 法索司他(firsocostat,GS-0976)逆转了临床观察到的脂肪肝病理表现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease. Owing to limited available treatment options, novel pre-clinical models for target selection and drug validation are warranted. We have established and extensively characterized a primary human steatotic hepatocyte in vitro model system that could guide the development of treatment strategies for MASLD. METHODS: Cryopreserved primary human hepatocytes from five donors varying in sex and ethnicity were cultured with free fatty acids in a 3D collagen sandwich for 7 days and the development of MASLD was followed by assessing classical hepatocellular functions. As proof of concept, the effects of the drug firsocostat (GS-0976) on in vitro MASLD phenotypes were evaluated. RESULTS: Incubation with free fatty acids induced steatosis, insulin resistance, mitochondrial dysfunction, inflammation, and alterations in prominent human gene signatures similar to patients with MASLD, indicating the recapitulation of human MASLD in this system. The application of firsocostat rescued clinically observed fatty liver disease pathologies, highlighting the ability of the in vitro system to test the efficacy and potentially characterize the mode of action of drug candidates. CONCLUSIONS: Altogether, our human MASLD in vitro model system could guide the development and validation of novel targets and drugs for the treatment of MASLD. IMPACT AND IMPLICATIONS: Due to low drug efficacy and high toxicity, clinical treatment options for metabolic dysfunction-associated steatotic liver disease (MASLD) are currently limited. To facilitate earlier stop-go decisions in drug development, we have established a primary human steatotic hepatocyte in vitro model. As the model recapitulates clinically relevant MASLD characteristics at high phenotypic resolution, it can serve as a pre-screening platform and guide target identification and validation in MASLD therapy.
引用
- Kwon Y, Gottmann P, Wang S, et al. Induction of steatosis in primary human hepatocytes recapitulates key pathophysiological aspects of metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2024. PMID: 38977136. doi:10.1016/j.jhep.2024.06.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。